List of drugs approved by FDA in 2022 (from January 2022 to March 2022)
January 2022
Drug Name | Active Ingredient | Company | FDA approved uses | Approval Date | Extra information |
Quviviq | Daridorexant | Indorsia Ltd. | To treat insomnia | January 7, 2022 | It is a dual orexin receptor antagonist. Tablet- 25 mg, 50 mg. |
Cibinqo | Abrocitinib | Pfizer Inc. | For Atopic dermatitis | January 14, 2022 | JAK (Janus Kinase)1 inhibitor. Tablet- 50, 100 and 200 mg. |
Ryaltris | Mometasone furoate and olapatdine HCL | Glenmark Pharmaceutical Inc. | Seasonal allergic rhinitis in patients of age 12 years and older. | January 13, 2022 | Mometasone furoate is corticosteroid and olapatadine is histamine (H1) receptor inhibitor. Nasal spray |
Kimmtrak | Tebentafusp-teben | Immunocore | For unresectable or metastatic uveal melanoma | January 25, 2022 | Bispecific gp-100 peptide-HLA-directed Cd3 T cell engager. Injection. |
Vabysmo | Faricimab-svoa | Genetech | To treat neovascular age-related macular degeneration and diabetic macular edema. | January 28, 2022 | It is a bispecific antibody which inhibits VEGF (vascular endothelial growth factor) and angiopoietin-2 pathway. Intravitreal injection. |
Slikevax | Moderna Covid-19 vaccine | Moderna, Inc. | Prevention of COVID-19 | January 31, 2022 | mRNA vaccine for active immunization against COVID-19. |
February 2022
Enjaymo | Sutimlimab-jome | Sanofi | To decrease need for transfusion of red blood cells due to hemolysis in cold agglutinin disease. | February 4, 2022 | Classical complement inhibitor. For intravenous use. |
Fleqsuvy | Baclofen | Azurity Pharmaceutical Inc. | For spasticity | February 4, 2022 | GABA agonist. Oral suspension. |
Pyrukynd | Mitapivat | Agios pharmaceutical Inc. | To treat hemolytic anemia. In pyruvate kinase deficiency | February 17, 2022 | Activates pyruvate kinase. Tablet- 5, 20 and 50 mg. |
Norliqva | Amlodipine besylate | CMP Pharma, Inc. | For hypertension in patients 6 years and older. | February 24, 2022 | Amlodipine is calcium channel blocker. First FDA approved liquid solution of amlodipine. |
Releuko | Filgrastim- ayow | Kashiv Biosciences LLC. | Neutropenia | February 25, 2022 | Leukocyte growth factor. SC (subcutaneous) or IV use. |
Carvykti | Ciltacabtageneautoleucel | Janssen Biotech Inc. | Multiple myeloma | February 28, 2022 | Genetically modified autologous T-cell immunotherapy which is BCMA directed. Suspension of IV infusion. |
Vonjo | Pacritinib | CTI Biopharma Corp. | Primary or secondary myelofibrosis in adults with low platelet count. | February 28, 2022 | JAK 2/FLT3 multikinase inhibitor. Capsules- 100 mg |
March 2022
Adlarity | Donepezil | Corium Inc. | Mild, moderate, and severe dementia in Alzheimer’s disease. | March 11, 2022 | Acetylcholinesterase inhibitor. First and only once-weekly transdermal patches. |
Nasonex 24 Hour Allergy | Mometasone furoate hydrate | Perrigo Company Plc | Allergic Rhinitis. | March 11, 2022 | It is a corticosteroid. Nasal spray available OTC. |
Ztalmy | Ganaxolone | Marinus Pharmaceuticals Inc. | To treat seizure in CDKL-5 deficiency disorder (CDD). | March 18, 2022 | Neuroactive steroid GABA- A receptor positive modulator. Oral suspension |
Opdualag | Nivolumab and ritalumab | Bristol Myers Squibb | Unresectable or metastatic melanoma. | March 18, 2022 | Nivolumab is PD-1 (programmed death receptor-10 blocking antibody and ritalumab is LAG-3 (lymphocyte activation gene-3) blocking antibody. IV injection |
Xelstrym | Dextroamphetamine | Noven pharmaceuticals Inc. | For ADHD (attention deficit hyperactivity disorder). | March 22, 2022 | CNS stimulant. Transdermal system |
Hyftor | Sirolimus | Nobelpharma America LLC. | Facial angiofibroma associated with tuberous sclerosis. | March 22, 2022 | mTOR inhibitor immunosuppressant. Topical gel |
Pluvicto | Lutetium (177 lu) vipivotide tetraxetan | Novartis | Prostate cancer | March 23, 2022 | Radioligand therapeutic agent. IV injection |
Tlando | Tesotosterone | Antares Pharma Inc. | For hypogonadism in male | March 28, 2022 | Testosterone is androgen. Available as capsule. |
References
- https://www.prnewswire.com/news-releases/cmp-pharma-inc-announces-that-norliqva-the-first-and-only-fda-approved-liquid-solution-of-amlodipine-is-now-available-301559346.html
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208712s000lbl.pdf
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761082s000lbl.pdf
- https://www.clinicaltrialsarena.com/comment/corium-adlarity-fda-alzheimers/
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215904s000lbl.pdf
- https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2022
- https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2022
- https://www.drugs.com/tlando.html